GlassScriptPhysician profile
Ardeshir Edward Nadimi
NPI 1992190417
$2,959.41
in general payments reported to CMS, 2019-2025
22 companies · $618 in 2025
The $618 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2020: $23.60 · 2021: $175 · 2022: $650 · 2023: $859 · 2024: $536 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.37 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.08 | 2022-2025 | |
| Janssen Biotech, INC. | $402.41 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Journey Medical Corporation | $249.85 | 2022 | |
| Genzyme Corporation | $232.12 | 2022-2024 | |
| Leo Pharma INC. | $215.63 | 2022-2024 | Adbry |
| Galderma Laboratories, L.P. | $207.02 | 2023-2025 | Epsolay, Aklief, Nemluvio |
| Eli Lilly and Company | $175.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.61 | 2023 | Spevigo |
| Incyte Corporation | $111.78 | 2022-2025 | Opzelura |
| Allergan, INC. | $97.33 | 2019 | |
| Lilly USA, LLC | $95.43 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Convatec INC. | $75.80 | 2024 | |
| Arcutis Biotherapeutics, INC. | $74.64 | 2023-2025 | Zoryve |
| Ucb, INC. | $71.07 | 2025 | Bimzelx |
| Amgen INC. | $57.97 | 2023 | Enbrel, Otezla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $57.23 | 2022-2025 | |
| Biofrontera INC. | $45.67 | 2025 | |
| Organogenesis INC. | $42.53 | 2023 | Puraply |
| Eisai INC. | $23.60 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $23.59 | 2022 | |
| Merz North America, INC. | $22.62 | 2025 | |
| Epi Health, LLC | $17.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ardeshir Nadimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.